Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A significant number of patients hospitalized for HFrEF have worsening hemodynamics and/or worsening renal function, which might lead to reluctance with initiating or continuing hemodynamically active therapies.
“Nevertheless, a significant number of patients hospitalized for HFrEF have worsening hemodynamics and/or worsening renal function, which might lead to reluctance with initiating or continuing hemodynamically active therapies.14-16”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [16]
The paper’s “Risks of Hypotension” section (page unavailable) says symptomatic hypotension may make providers unwilling to optimize therapy, and it discusses low blood pressure in patients hospitalized for worsening HFrEF. It does not establish that a significant number of hospitalized patients develop worsening hemodynamics or worsening renal function, or link worsening renal function specifically to reluctance to initiate or continue therapy. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029 · see citing works
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · see citing works
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109 · see citing works
Swedberg, K. B., & KJEKSHUS, J. K. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762 · see citing works
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725 · see citing works
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108 · see citing works
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604 · see citing works
Effect of Nesiritide in Patients with Acute Decompensated Heart Failure
O'Connor, C. M., Starling, R. C., Hernandez, A. F., Armstrong, P. W., Dickstein, K., Hasselblad, V., Heizer, G., Michel Komajda, N., Massie, B. M., McMurray, J. J. V., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100171 · Cited by 1,249 · see citing works
Self-citationPacker, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G. F., Horowitz, J. D., Massie, B. M., Rydén, L., Thygesen, K., & Uretsky, B. F. (1999) · Circulation · doi:10.1161/01.cir.100.23.2312 · Cited by 1,244 · see citing works
Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240 · see citing works
Cuffe, M. S. (2002) · JAMA · doi:10.1001/jama.287.12.1541 · Cited by 1,179 · see citing works
McMurray, J. J. V., Östergren, J., Swedberg, K. B., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer (2003) · The Lancet · Cited by 1,043 · see citing works
A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure
The Beta-Blocker Evaluation of Survival Trial Investigators (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442202 · Cited by 1,005 · see citing works
Gheorghiade, M., Abraham, W. T., Albert, N. M., Greenberg, B., O’Connor, C. M., She, L., Stough, W. G., Yancy, C. W., Young, J. B., Fonarow, G. C., et al. (2006) · JAMA · doi:10.1001/jama.296.18.2217 · Cited by 974 · see citing works
Self-citationTeerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G. S., Greenberg, B., Ponikowski, P. P., Unemori, E., Voors, A. A., Adams, K. F., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61855-8 · Cited by 919 · see citing works
Chen, J., Normand, S. T., Wang, Y., & Krumholz, H. M. (2011) · JAMA · doi:10.1001/jama.2011.1474 · Cited by 742 · see citing works
Maggioni, A. P., Anker, S. D., Dahlström, U., Filippatos, G. S., Ponikowski, P. P., Zannad, F. M., Amir, O., Chioncel, O., Crespo‐Leiro, M. G., Dróżdż, J., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft134 · Cited by 666 · see citing works
Califf, R. M., Adams, K. F., McKenna, W. J., Gheorghiade, M., Uretsky, B. F., McNulty, S. E., Darius, H., Schulman, K. A., Zannad, F. M., Handberg, E. M., et al. (1997) · American Heart Journal · doi:10.1016/s0002-8703(97)70105-4 · Cited by 661 · see citing works
Self-citationComparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure
Packer, M., Califf, R. M., Konstam, M. A., Krum, H., McMurray, J. J. V., Rouleau, J. L., & Swedberg, K. B. (2002) · Circulation · doi:10.1161/01.cir.0000029801.86489.50 · Cited by 615 · see citing works
Heart failure etiology and response tomilrinone in decompensated heart failure
Felker, G. M., Benza, R. L., Chandler, A. B., Leimberger, J. D., Cuffe, M. S., Califf, R. M., Gheorghiade, M., & O’Connor, C. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02968-6 · Cited by 517 · see citing works
Self-citationRolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure
Massie, B. M., O’Connor, C. M., Metra, M., Ponikowski, P. P., Teerlink, J. R., Cotter, G., Davison, B. A., Cleland, J. G. F., Givertz, M. M., Voors, A. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912613 · Cited by 516 · see citing works
Packer, M., Colucci, W. S., Fisher, L. D., Massie, B. M., Teerlink, J. R., Young, J. B., Padley, R. J., Thakkar, R. B., Delgado‐Herrera, L., Salon, J. E., et al. (2013) · JACC Heart Failure · doi:10.1016/j.jchf.2012.12.004 · Cited by 437 · see citing works
Cohn, J. N., Pfeffer, M. A., Rouleau, J. L., Sharpe, N., Swedberg, K. B., Straub, M., Wiltse, C. G., Wright, T. J., & for the MOXCON Investigators (2003) · European Journal of Heart Failure · doi:10.1016/s1388-9842(03)00163-6 · Cited by 382 · see citing works
Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure
McMurray, J. J. V., Teerlink, J. R., Cotter, G., Bourge, R. C., Cleland, J. G. F., Jondeau, G., Krum, H., Metra, M., O’Connor, C. M., Parker, J. D., et al. (2007) · JAMA · doi:10.1001/jama.298.17.2009 · Cited by 357 · see citing works
Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure
McMurray, J. J. V., Pitt, B., Latini, R., Maggioni, A. P., Solomon, S. D., Keefe, D. L., Ford, J. H., Verma, A., & Lewsey, J. (2008) · Circulation Heart Failure · doi:10.1161/circheartfailure.107.740704 · Cited by 354 · see citing works
Self-citationGheorghiade, M., Böhm, M., Greene, S. J., Fonarow, G. C., Lewis, E. F., Zannad, F. M., Solomon, S. D., Baschiera, F., Botha, J., Hua, T. A., et al. (2013) · JAMA · doi:10.1001/jama.2013.1954 · Cited by 325 · see citing works
Self-citationGheorghiade, M., Greene, S. J., Filippatos, G. S., Erdmann, E., Ferrari, R., Levy, P. D., Maggioni, A. P., Nowack, C., & Mebazaa, A. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs093 · Cited by 124 · see citing works
Self-citationAmbrosy, A., Vaduganathan, M., Mentz, R., Greene, S., Subacius, H., Konstam, M., Maggioni, A., Swedberg, K., & Gheorghiade, M. (2013) · American Heart Journal · doi:10.1016/j.ahj.2012.11.004 · Cited by 98 · see citing works
Self-citationHeart failure therapy at a crossroad: are there limits to the neurohormonal model?
Mehra, M. R., Uber, P. A., & Francis, G. S. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00245-6 · Cited by 78 · see citing works
Nanas, J. N., Alexopoulos, G. P., ANASTASIOU‐NANA, M. I., Karidis, K., Tirologos, A., Zobolos, S., Pirgakis, V., Anthopoulos, L., Sideris, D. A., Stamatelopoulos, S. F., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01025-1 · Cited by 76 · see citing works
Anand, I. S., Tam, S. W., Rector, T. S., Taylor, A. L., Sabolinski, M. L., Archambault, W. T., Adams, K. F., Olukotun, A. Y., Worcel, M., & Cohn, J. N. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.109 · Cited by 64 · see citing works
Böhm, M., BORER, J. S., Camm, A. J., Ford, I., Lloyd, S. M., Michel Komajda, N., Tavazzi, L., Talajic, M. R., Lainščak, M., Reil, J., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.258 · Cited by 61 · see citing works
Ford, I., Robertson, M., Michel Komajda, N., Böhm, M., BORER, J. S., Tavazzi, L., & Swedberg, K. B. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.02.001 · Cited by 51 · see citing works
Acute Heart Failure Syndromes and Coronary Perfusion
Beohar, N., Erdogan, A., Lee, D. C., Sabbah, H. N., Kern, M. J., Teerlink, J. R., Bonow, R. O., & Gheorghiade, M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.037 · Cited by 48 · see citing works
Self-citationRossignol, P., Girerd, N., Gregory, D., Massaro, J. M., Konstam, M. A., & Zannad, F. M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.169 · Cited by 39 · see citing works
Neurohormonal Inhibition in Heart Failure: Insights from Recent Clinical Trials
Gheorghiade, M., Luca, L. D., & Bonow, R. O. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.059 · Cited by 31 · see citing works
Self-citationMak, G. J., Murphy, N. F., Ali, A. S., Walsh, A., O’Loughlin, C., Conlon, C. M., McCaffrey, D. J., Ledwidge, M. T., & McDonald, K. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.03.003 · Cited by 19 · see citing works
Vaduganathan, M., & Prasad, V. K. (2014) · JAMA · doi:10.1001/jama.2014.15221 · Cited by 5 · see citing works
Self-citationVaduganathan, M., Greene, S. J., Fonarow, G. C., Bonow, R. O., Butler, J., & Gheorghiade, M. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.01.041 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Mitochondrial function as a therapeutic target in heart failure
Brown, D. A., Perry, J. B., Allen, M. E., Sabbah, H. N., Stauffer, B. L., Shaikh, S. R., Cleland, J. G. F., Colucci, W. S., Butler, J., Voors, A. A., et al. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.203 · Cited by 811 · see citing works
Self-citationGheorghiade, M., Greene, S. J., Butler, J., Filippatos, G. S., Lam, C. S. P., Maggioni, A. P., Ponikowski, P. P., Shah, S. J., Solomon, S. D., Kraigher‐Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 399 · see citing works
Self-citationMcDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Heckman, G. A., Howlett, J. G., Koshman, S. L., Lepage, S., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.017 · Cited by 287 · see citing works
D’Elia, E., Iacovoni, A., Vaduganathan, M., Lorini, F. L., Perlini, S., & Senni, M. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.799 · Cited by 169 · see citing works
Self-citationBhagat, A. A., Greene, S. J., Vaduganathan, M., Fonarow, G. C., & Butler, J. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.06.011 · Cited by 169 · see citing works
Self-citationCoenzyme Q10 and Heart Failure
Sharma, A., Fonarow, G. C., Butler, J., Ezekowitz, J. A., & Felker, G. M. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002639 · Cited by 150 · see citing works
Self-citationSenni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Anand, I. S., Duino, V., Sarkar, A., Shi, V. C., & Charney, A. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1054 · Cited by 72 · see citing works
Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs
Kithcart, A. P., & MacRae, C. A. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.01.004 · Cited by 64 · see citing works
Developing New Treatments for Heart Failure
Gheorghiade, M., Larson, C. J., Shah, S. J., Greene, S. J., Cleland, J. G. F., Colucci, W. S., Dunnmon, P. M., Epstein, S. E., Kim, R. J., Parsey, R. V., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002727 · Cited by 64 · see citing works
Self-citationPitoulis, F. G., Watson, S. A., Perbellini, F., & Terracciano, C. M. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz341 · Cited by 64 · see citing works
Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure
Greene, S. J., Sabbah, H. N., Butler, J., Voors, A. A., Albrecht-Küpper, B. E., Düngen, H., Dinh, W., & Gheorghiade, M. (2015) · Heart Failure Reviews · doi:10.1007/s10741-015-9522-7 · Cited by 58 · see citing works
Self-citationDeb, P. K., Deka, S., Borah, P., Abed, S. N., & Klotz, K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190716100509 · Cited by 54 · see citing works
Skouri, H. N., Girerd, N., Monzo, L., Petrie, M. C., Böhm, M., Adamo, M., Müllens, W., Savarese, G., Yılmaz, M. B., Amir, O., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3618 · Cited by 53 · see citing works
Self-citationGe, Z., Li, A., McNamara, J. W., dos Remedios, C. G., & Lal, S. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09806-0 · Cited by 45 · see citing works
Partial Adenosine A1 Agonist in Heart Failure
Dinh, W., Albrecht-Küpper, B. E., Gheorghiade, M., Voors, A. A., van der Laan, M., & Sabbah, H. N. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_83 · Cited by 34 · see citing works
Self-citationLteif, C., Ataya, A., & Duarte, J. D. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020633 · Cited by 29 · see citing works
New drugs in preclinical and early stage clinical development in the treatment of heart failure
Tamargo, J. L., Caballero, R., & Delpón, E. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1551357 · Cited by 28 · see citing works
Vaduganathan, M., Cheema, B. S., Cleveland, E., Sankar, K. N., Subacius, H. P., Fonarow, G. C., Solomon, S. D., Lewis, E. F., Greene, S. J., Maggioni, A. P., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.973 · Cited by 26 · see citing works
Self-citationCRRL269: a novel designer and renal-enhancing pGC-A peptide activator
Chen, Y., Harty, G. J., Huntley, B. K., Iyer, S. R., Heublein, D. M., Harders, G. E., Meems, L. M. G., Pan, S., Sangaralingham, S. J., Ichiki, T., et al. (2017) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00286.2017 · Cited by 23 · see citing works
Martín‐Pérez, M., Michel, A., Ma, M., & Rodríguez, L. A. G. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028750 · Cited by 20 · see citing works
Screening drugs for myocardial disease in vivo with zebrafish: an expert update
Zhao, Y., Zhang, K., Sips, P. Y., & MacRae, C. A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1577815 · Cited by 19 · see citing works
Considerations for Clinical Trials Targeting the Myocardial Interstitium
Lewis, G. A., Dodd, S. R., Naish, J. H., Selvanayagam, J. B., Dweck, M. R., & Miller, C. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2019.03.034 · Cited by 18 · see citing works
The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two (or more) Birds on One Stone
Caruso, L., Nadur, N. F., da Fonseca, M. B., Ferreira, L. A., Lacerda, R. B., Graebin, C. S., & Kümmerle, A. E. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220201151248 · Cited by 17 · see citing works
Rueda, P., Merlin, J., Chimenti, S., Félétou, M., Paysant, J., White, P. J., Christopoulos, A., Sexton, P. M., Summers, R. J., Charman, W. N., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628060 · Cited by 15 · see citing works
Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Vaduganathan, M., & Desai, A. S. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0784-z · Cited by 9 · see citing works
Self-citationUtility of positron emission tomography for drug development for heart failure
Papadimitriou, L., Smith-Jones, P. M., Sarwar, C. M. S., Marti, C. N., Yaddanapudi, K., Skopicki, H. A., Gheorghiade, M., Parsey, R. V., & Butler, J. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.02.016 · Cited by 9 · see citing works
Self-citationTsutsui, H., Momomura, S., Saito, Y., Ito, H., Yamamoto, K., Sakata, Y., Ohishi, T., Iimori, T., Kitamura, T., & on behalf of the PARALLEL-HF Investigators (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0349 · Cited by 8 · see citing works
Tsutsui, H., Momomura, S., Saito, Y., Ito, H., Yamamoto, K., Sakata, Y., Ohishi, T., Iimori, T., & Kitamura, T. (2024) · Journal of Cardiology · doi:10.1016/j.jjcc.2024.09.002 · Cited by 6 · see citing works
Qoreishi, S. H., Tabari, M. A. K., Găman, M., & Kazeminejad, A. (2024) · Avicenna Journal of Medical Biotechnology · doi:10.18502/ajmb.v16i3.15740 · Cited by 5 · see citing works
Зуева, И. Б., & O.Ju., P. (2020) · Vrach · doi:10.29296/25877305-2020-04-06 · Cited by 3 · see citing works
Renin–Angiotensin–Aldosterone System as an Old New Target in Heart Failure Therapy
Kov́acs, Á., & Barta, J. (2023) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-14952-8_19 · Cited by 2 · see citing works
Ishii, T., Matsue, Y., Matsunaga, Y., Iekushi, K., Homma, Y., & Morita, Y. (2023) · Heart and Vessels · doi:10.1007/s00380-023-02304-2 · Cited by 2 · see citing works
Coenzyme Q10 and Selenium in Heart Failure – A New Perspective
Bolog, M. (2019) · Internal Medicine · doi:10.2478/inmed-2019-0083 · Cited by 1 · see citing works
New heart failure pharmacotherapy in clinical trials: a hope in progress
Selim, A. M. A., Zolty, R., & Chatzizisis, Y. S. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1358614 · Cited by 1 · see citing works
Mihai Gheorghiade, MD—Life and Concepts
Pang, P. S., Collins, S. P., Butler, J., & Chioncel, O. (2018) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000797
Self-citationMechanisms of Cardiorenal Syndrome: From Molecular Pathways to Novel Therapeutics
Ichiki, T., Chen, Y., & Burnett, J. C. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-21033-5_3
Wallner, M., & Ponikowski, P. P. (2019) · International Cardiovascular Forum Journal · doi:10.17987/icfj.v18i0.613
Development of a novel therapy for systolic heart failure
Pollock, C., Wang, X., Alsaraji, H., Menassa, J., Mbogo, G. W., Angage, D., Richards, B. J., Glab, J., Datta, K. K., Theodoridis, L., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00284-6
- Authors
- Vaduganathan, M., Butler, J., Pitt, B., & Gheorghiade, M.
- Affiliations
- Northwestern University (US)
- Venue
- Circulation: Heart Failure
- Published
- 2015-07
- Volume
- 8
- Issue
- 4
- Pages
- 826-831
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W1951293753
- Cited by
- 38
- References
- 39
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 1 · 2019: 9 · 2018: 3 · 2017: 6 · 2016: 6 · 2015: 2
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation Heart Failure (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- heart failure, drug development, heart failure treatment, clinical trials
- MeSH terms
- Animals, Cardiovascular Agents, Heart Failure, Hemodynamics, Humans, Hypotension, Risk Factors, Stroke Volume, Drug Design, Ventricular Function, Left, Risk Assessment, Ventricular Remodeling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
